St. Louis Financial Planners Asset Management LLC Has $975,000 Stake in CVS Health Corporation $CVS

St. Louis Financial Planners Asset Management LLC cut its position in shares of CVS Health Corporation (NYSE:CVS) by 42.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,279 shares of the pharmacy operator’s stock after selling 8,876 shares during the quarter. St. Louis Financial Planners Asset Management LLC’s holdings in CVS Health were worth $975,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its position in CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares in the last quarter. Corundum Trust Company INC acquired a new position in shares of CVS Health in the 3rd quarter valued at about $29,000. GoalVest Advisory LLC bought a new stake in shares of CVS Health during the 4th quarter valued at about $32,000. Finally, Front Row Advisors LLC grew its stake in CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 371 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE CVS opened at $71.58 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The company has a fifty day simple moving average of $77.48 and a 200 day simple moving average of $77.78. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The company has a market cap of $91.07 billion, a P/E ratio of 51.87, a PEG ratio of 0.75 and a beta of 0.49.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the firm earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Sell-side analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.7%. CVS Health’s payout ratio is 192.75%.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS’s board declared a quarterly dividend of $0.665/share (payable May 4; record April 23), a cash-return signal that can support the share price. CVS Health declares quarterly dividend
• Positive Sentiment: Brokerages’ consensus rating sits at “Moderate Buy,” providing analyst support amid volatility. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Positive Sentiment: CVS announced a $2.24M investment to expand health access in west Charlotte — a community-health initiative that highlights growth of care-delivery and outreach programs. CVS Health invests $2.24 million in west Charlotte health initiative
• Neutral Sentiment: Media roundup and dividend-focused pieces are covering CVS alongside other dividend payers — keeps the name in income-focused investor conversations but is unlikely to move shares materially. Dividend roundup: JPMorgan Chase, Micron Technology, CVS Health, Broadcom, and more
• Neutral Sentiment: Coverage calling CVS a “trending” stock and roundups on healthcare stock picks keep investor attention but are mixed in tone — watch for conviction from earnings/forward guidance. CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Company exec discussed AI policy and quality initiatives — signals operational focus but not an immediate catalyst. CVS Health/Aetna executive discusses company AI policy and the harder truth about quality
• Negative Sentiment: Bernstein Litowitz filed a racketeering class action against CaremarkPCS and CVS alleging fraud of PBM customers — this is a material legal overhang that could prompt costs, fines or settlements. Bernstein Litowitz Berger & Grossmann Announces Filing of Racketeering Class Action Against CaremarkPCS and CVS Health Corporation
• Negative Sentiment: Tennessee legislation targeting pharmacy benefit managers (PBMs) could force store closures — state estimates say 100+ CVS locations might be affected, raising local revenue and access risks. TN bill targeting pharmacy benefit managers could threaten closure of 100+ CVS stores in the state
• Negative Sentiment: Lawmakers and a U.S. Representative (Aftyn Behn) are calling for investigations and have heard conflicting testimony about CVS claims that pharmacies will close — increased regulatory scrutiny and political risk. Rep. Aftyn Behn calls for an investigation into CVS claims that pharmacies are closing
• Negative Sentiment: Local reporting and commentary examine whether lawmakers can curb CVS/PBM influence on drug pricing — signals broader regulatory attention on CVS’s PBM business. Could lawmakers crack CVS’s grip on the prescription drug supply chain?

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Argus dropped their price target on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday, March 13th. Morgan Stanley lifted their price objective on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Twenty investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.05.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.